These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19773789)

  • 1. Lipid lowering: education is key.
    Fuster V; Mearns BM
    Nat Rev Cardiol; 2009 Oct; 6(10):609-10. PubMed ID: 19773789
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary prevention with over-the-counter statins: a cautionary tale.
    Davidoff F
    Clin Pharmacol Ther; 2005 Sep; 78(3):218-20. PubMed ID: 16153392
    [No Abstract]   [Full Text] [Related]  

  • 3. In the clinic. Dyslipidemia.
    Kopin LA; Pearson TA
    Ann Intern Med; 2007 Sep; 147(5):ITC9-1-ITC9-16. PubMed ID: 17785482
    [No Abstract]   [Full Text] [Related]  

  • 4. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins.
    Barter PJ; Rye KA
    Circulation; 2006 Sep; 114(12):1315-20; discussion 1320. PubMed ID: 16982953
    [No Abstract]   [Full Text] [Related]  

  • 5. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
    Reiner Z
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
    [No Abstract]   [Full Text] [Related]  

  • 6. Over-the-counter statins? Sorting out the issues.
    Hughes S
    J Cardiovasc Nurs; 2004; 19(6):430-1. PubMed ID: 15529067
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk factor management: a practice guide.
    Perk J
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S24-8. PubMed ID: 19675433
    [No Abstract]   [Full Text] [Related]  

  • 8. Residual cardiac risk reduction beyond lipid lowering.
    Pagourelias ED; Gossios TD; Tziomalos K; Karagiannis A; Geleris P; Athyros VG
    Hellenic J Cardiol; 2011; 52(3):197-203. PubMed ID: 21642067
    [No Abstract]   [Full Text] [Related]  

  • 9. Is it appropriate to make statins available over the counter? Over-the-counter statins are worth considering in primary prevention of cardiovascular disease.
    Gotto AM
    Circulation; 2006 Sep; 114(12):1310-4; discussion 1314. PubMed ID: 16982952
    [No Abstract]   [Full Text] [Related]  

  • 10. Update on statins and other lipid-lowering drugs.
    Miller CA
    Geriatr Nurs; 2001; 22(5):276-7. PubMed ID: 11606910
    [No Abstract]   [Full Text] [Related]  

  • 11. A quick fix?
    Lynch E
    Nurs Stand; 2006 Mar 15-21; 20(27):20-1. PubMed ID: 16566332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dyslipidemias and statins: from guidelines to clinical practice. An updated review of the literature].
    Lucchi T; Vergani C
    G Ital Cardiol (Rome); 2014 Mar; 15(3):149-60. PubMed ID: 24770428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [2016 European Society of Cardiology guidelines for the management of dyslipidemias].
    Ferrières J
    Presse Med; 2017; 46(7-8 Pt 1):688-696. PubMed ID: 28502376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial.
    Persell SD; Brown T; Lee JY; Shah S; Henley E; Long T; Luther S; Lloyd-Jones DM; Jean-Jacques M; Kandula NR; Sanchez T; Baker DW
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):560-6. PubMed ID: 26555123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Food and Drug Administration and over-the-counter statins: an opportunity lost?
    Pickering TG
    J Clin Hypertens (Greenwich); 2008 Mar; 10(3):245-8. PubMed ID: 18326969
    [No Abstract]   [Full Text] [Related]  

  • 16. [Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines].
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR;
    Semergen; 2015 Apr; 41(3):149-57. PubMed ID: 25450438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over-the-counter statins.
    Aslam F
    Lancet; 2004 Jul 31-Aug 6; 364(9432):411-2. PubMed ID: 15288727
    [No Abstract]   [Full Text] [Related]  

  • 18. [Lipid management--treatment goal and strategy].
    Koshiyama H
    Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Under-prescription of statins in patients with non-alcoholic fatty liver disease.
    Del Ben M; Baratta F; Polimeni L; Pastori D; Loffredo L; Averna M; Violi F; Angelico F
    Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):161-167. PubMed ID: 27914698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.
    Mahabadi AA; Möhlenkamp S; Lehmann N; Kälsch H; Dykun I; Pundt N; Moebus S; Jöckel KH; Erbel R;
    JACC Cardiovasc Imaging; 2017 Feb; 10(2):143-153. PubMed ID: 27665163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.